As of 2024-12-15, the EV/EBITDA ratio of Castle Biosciences Inc (CSTL) is 58.33. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CSTL's latest enterprise value is 723.99 mil USD. CSTL's TTM EBITDA according to its financial statements is 12.41 mil USD. Dividing these 2 quantities gives us the above CSTL EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 11.4x | 10.7x |
| Forward P/E multiples | 9.6x - 9.9x | 9.8x |
| Fair Price | 7.26 - 8.08 | 7.56 |
| Upside | -74.9% - -72.0% | -73.8% |
| Date | EV/EBITDA |
| 2024-12-09 | 62.94 |
| 2024-12-06 | 63.57 |
| 2024-12-05 | 65.76 |
| 2024-12-04 | 65.13 |
| 2024-12-03 | 62.65 |
| 2024-12-02 | 64.04 |
| 2024-11-29 | 61.52 |
| 2024-11-27 | 61.88 |
| 2024-11-26 | 62.17 |
| 2024-11-25 | 59.78 |
| 2024-11-22 | 60.46 |
| 2024-11-21 | 58.36 |
| 2024-11-20 | 57.39 |
| 2024-11-19 | 58.33 |
| 2024-11-18 | 56.15 |
| 2024-11-15 | 56.60 |
| 2024-11-14 | 62.76 |
| 2024-11-13 | 64.95 |
| 2024-11-12 | 67.16 |
| 2024-11-11 | 69.42 |
| 2024-11-08 | 68.31 |
| 2024-11-07 | 68.36 |
| 2024-11-06 | 66.89 |
| 2024-11-05 | 63.48 |
| 2024-11-04 | 69.10 |
| 2024-11-01 | 67.99 |
| 2024-10-31 | 71.42 |
| 2024-10-30 | 71.13 |
| 2024-10-29 | 69.42 |
| 2024-10-28 | 66.30 |
| 2024-10-25 | 63.98 |
| 2024-10-24 | 64.95 |
| 2024-10-23 | 65.22 |
| 2024-10-22 | 65.99 |
| 2024-10-21 | 65.11 |
| 2024-10-18 | 66.84 |
| 2024-10-17 | 67.79 |
| 2024-10-16 | 69.39 |
| 2024-10-15 | 68.74 |
| 2024-10-14 | 70.50 |
| 2024-10-11 | 63.84 |
| 2024-10-10 | 57.05 |
| 2024-10-09 | 58.06 |
| 2024-10-08 | 60.91 |
| 2024-10-07 | 59.80 |
| 2024-10-04 | 59.42 |
| 2024-10-03 | 57.32 |
| 2024-10-02 | 57.43 |
| 2024-10-01 | 56.57 |
| 2024-09-30 | 57.54 |